Nippon Shinyaku
Market Cap
US$5.5b
Last Updated
2020/02/23 02:37 UTC
Data Sources
Company Financials +
Executive Summary
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally.
Rewards
Risk Analysis
No risks detected for NPPN.Y from our risk checks.
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Nippon Shinyaku's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NPPN.Y has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
n/a
NPPN.Y
-0.5%
US Pharmaceuticals
-1.1%
US Market
1 Year Return
36.2%
NPPN.Y
6.2%
US Pharmaceuticals
17.9%
US Market
Return vs Industry: NPPN.Y exceeded the US Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: NPPN.Y exceeded the US Market which returned 17.9% over the past year.
Shareholder returns
| NPPN.Y | Industry | Market | |
|---|---|---|---|
| 7 Day | n/a | -0.5% | -1.1% |
| 30 Day | n/a | -1.0% | 1.4% |
| 90 Day | n/a | 5.7% | 6.9% |
| 1 Year | 36.2%36.2% | 8.9%6.2% | 20.3%17.9% |
| 3 Year | 58.4%58.4% | 25.4%16.6% | 47.8%38.3% |
| 5 Year | n/a | 29.7%15.7% | 71.9%53.0% |
Price Volatility Vs. Market
How volatile is Nippon Shinyaku's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Nippon Shinyaku undervalued compared to its fair value and its price relative to the market?
26.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NPPN.Y ($21.43) is trading below our estimate of fair value ($29.24)
Significantly Below Fair Value: NPPN.Y is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NPPN.Y is poor value based on its PE Ratio (39.8x) compared to the Pharmaceuticals industry average (21.6x).
PE vs Market: NPPN.Y is poor value based on its PE Ratio (39.8x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: NPPN.Y is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: NPPN.Y is overvalued based on its PB Ratio (4.4x) compared to the US Pharmaceuticals industry average (3x).
Next Steps
Future Growth
How is Nippon Shinyaku forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
17.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NPPN.Y's forecast earnings growth (17.9% per year) is above the savings rate (1.7%).
Earnings vs Market: NPPN.Y's earnings (17.9% per year) are forecast to grow faster than the US market (14.1% per year).
High Growth Earnings: NPPN.Y's earnings are forecast to grow, but not significantly.
Revenue vs Market: NPPN.Y's revenue (7.4% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: NPPN.Y's revenue (7.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NPPN.Y's Return on Equity is forecast to be low in 3 years time (16.9%).
Next Steps
Past Performance
How has Nippon Shinyaku performed over the past 5 years?
21.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NPPN.Y has high quality earnings.
Growing Profit Margin: NPPN.Y's current net profit margins (13.4%) are higher than last year (12.6%).
Past Earnings Growth Analysis
Earnings Trend: NPPN.Y's earnings have grown significantly by 21.4% per year over the past 5 years.
Accelerating Growth: NPPN.Y's earnings growth over the past year (10.7%) is below its 5-year average (21.4% per year).
Earnings vs Industry: NPPN.Y earnings growth over the past year (10.7%) exceeded the Pharmaceuticals industry 2.4%.
Return on Equity
High ROE: NPPN.Y's Return on Equity (10.9%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Nippon Shinyaku's financial position?
Financial Position Analysis
Short Term Liabilities: NPPN.Y's short term assets (¥116.7B) exceed its short term liabilities (¥23.8B).
Long Term Liabilities: NPPN.Y's short term assets (¥116.7B) exceed its long term liabilities (¥7.1B).
Debt to Equity History and Analysis
Debt Level: NPPN.Y is debt free.
Reducing Debt: NPPN.Y has not had any debt for past 5 years.
Debt Coverage: NPPN.Y has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NPPN.Y has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: NPPN.Y has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if NPPN.Y's debt is covered by short term assets.
Next Steps
Dividend
What is Nippon Shinyaku's current dividend yield, its reliability and sustainability?
0.94%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NPPN.Y's dividend (0.94%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: NPPN.Y's dividend (0.94%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stability and Growth of Payments
Stable Dividend: NPPN.Y's dividends per share have been stable in the past 10 years.
Growing Dividend: NPPN.Y's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (36.5%), NPPN.Y's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.1yrs
Average management tenure
CEO
Shigenobu Maekawa (66yo)
12.7yrs
Tenure
Mr. Shigenobu Maekawa has been President of Nippon Shinyaku Co., Ltd., since June 28, 2007. Mr. Maekawa served as Managing Director and General Manager of Finance & Accounting Division, Corporate Planning ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Representative Director | 12.7yrs | no data | 0.077% ¥4.3m | |
| Department Manager of Finance & Accounting Department and Corporate Officer | 0yrs | no data | no data | |
| Head of Administration Division & Director | 1.7yrs | no data | 0.0058% ¥319.8k | |
| MD. Head of Sales & Marketing Division and Director | 5.1yrs | no data | 0.0089% ¥492.2k | |
| General Manager of Personnel Dept. & Corporate Officer | 0yrs | no data | no data | |
| MD, Head of Research & Development Division and Director | 9.7yrs | no data | 0.019% ¥1.0m | |
| Corporate Officer & Head of Medical Supervisory Division | 0yrs | no data | no data | |
| Head of Resource Procurement | 5.7yrs | no data | 0.0082% ¥451.3k | |
| Head of Functional Food Division & Director | 5.1yrs | no data | 0.0074% ¥409.8k | |
| Head of Business Management & Director | 1.7yrs | no data | 0.0049% ¥270.7k |
5.1yrs
Average Tenure
66yo
Average Age
Experienced Management: NPPN.Y's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Representative Director | 12.7yrs | no data | 0.077% ¥4.3m | |
| Head of Administration Division & Director | 1.7yrs | no data | 0.0058% ¥319.8k | |
| MD. Head of Sales & Marketing Division and Director | 5.1yrs | no data | 0.0089% ¥492.2k | |
| MD, Head of Research & Development Division and Director | 9.7yrs | no data | 0.019% ¥1.0m | |
| Head of Resource Procurement | 5.7yrs | no data | 0.0082% ¥451.3k | |
| Head of Functional Food Division & Director | 5.1yrs | no data | 0.0074% ¥409.8k | |
| Head of Business Management & Director | 1.7yrs | no data | 0.0049% ¥270.7k | |
| Head of Global Business Division & Director | 1.1yrs | no data | 0.0050% ¥278.9k | |
| External Director | 7.1yrs | no data | 0.0024% ¥131.5k | |
| External Director | 6.7yrs | no data | 0.0024% ¥131.5k |
5.4yrs
Average Tenure
66yo
Average Age
Experienced Board: NPPN.Y's board of directors are considered experienced (5.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Nippon Shinyaku Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Nippon Shinyaku Co., Ltd.
- Ticker: NPPN.Y
- Exchange: OTCPK
- Founded: 1911
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥616.961b
- Listing Market Cap: JP¥5.524b
- Shares outstanding: 67.35m
- Website: https://www.nippon-shinyaku.co.jp
Number of Employees
Location
- Nippon Shinyaku Co., Ltd.
- 14, Nishinosho-Monguchi-cho
- Kisshoin
- Kyoto
- 601-8550
- Japan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4516 | TSE (The Tokyo Stock Exchange) | Yes | Common Stock | JP | JPY | Jan 1992 |
| NPPN.Y | OTCPK (Pink Sheets LLC) | UNSPONSORED ADR | US | USD | Nov 2016 |
Biography
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. Its products comprise Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company’s products also include Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; Regtect for maintaining alcohol abstinence; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Baynas for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; and Onetram and Tramal for cancer and chronic pain. In addition, it researches and develops, and markets drugs in the areas of urology, gynecology, otorhinolaryngology, and orthopedics. In addition, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/23 02:37 |
| End of Day Share Price | 2020/02/18 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.